미래에셋 김승민 - 2026-03-17 — 와이바이오

[미래에셋 김승민] AACR 2026 국내 기업 발표 세션/Title HLB이노베이션(Verismo) Apr 20 2026 10:15AM 세션: CTPL 03. Clinical Trials Plenary 3: Cellular Therapies and Complex Immunotherapies CT104 - Initial results of a first in human dose-escalation study of KIR-CAR in patients with advanced mesothelin-expressing solid tumors 알지노믹스 Apr 19 2026 3:00PM CTMS 03. Advanced Cellular and Immune-Based Therapeutics CT030. A phase 1b/2a, open-label, multicenter, randomized, dose escalation study evaluating the safety, tolerability and efficacy of RZ-001 in combination with valganciclovir (VGCV) and atezolizumab/bevacizumab in subjects with hepatocellular carcinoma 오름테라퓨틱 Apr 20 2026 9:00AM PO .ET07.01. Quantitative Pharmacology and Translational Modeling 1824. ORM-1153: A Next-Generation CD123-Targeting Degrader Antibody Conjugate (DAC) 삼성바이오에피스 Apr 20 2026 9:00AM PO .ET07.01. Quantitative Pharmacology and Translational Modeling 1815 / 3 - Nonclinical characterization of SBE303: A nectin-4 targeted antibody drug conjugate (ADC) with novel topoisomerase 1 inhibitor shows a favorable safety margin 와이바이오로직스 Apr 21 2026 9:00AM PO .IM01.15. Monoclonal Antibodies and Antibody-Cytokine Platforms 4334. AR170, a novel PD-1xVEGFxIL-2v tri-specific immunocytokine to redefine next generation cancer immunotherapy * 중요도는 일반적으로 CTPL > CTMS ≥ LBPO > PO CTPL: Clinical Trials Plenary. 임상 데이터 메인 구두 발표 CTMS: Clinical Trials Minisymposium. 임상 데이터 구두 발표 LBPO: Late-Breaking Poster. Regular 마감 이후 추가된 최신 포스터 PO: Poster Only. 일반적인 포스터 * 제보환영

출처

• [[260317_bioksm]] (원본 노트)